Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats
| Autor: | Zehra Eren, Mehmet Yalçin Günal, Elif Arı Bakir, Jale Coban, Berrak Çağlayan, Nur Ekimci, Sinem Ethemoglu, Ozgur Albayrak, Tuba Akdeniz, Gülderen Yanikkaya Demirel, Ertuğrul Kiliç, Gülçin Kantarci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Kidney & Blood Pressure Research, Vol 39, Iss 6, Pp 581-590 (2014) |
| Druh dokumentu: | article |
| ISSN: | 1420-4096 1423-0143 |
| DOI: | 10.1159/000368471 |
| Popis: | Background/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats. Methods: Forty male Sprague Dawley rats were divided into 5 groups of 8 rats each, namely the control (Group C), diabetes (Group D), aliskiren (Group A), paricalcitol (Group P), and aliskiren plus paricalcitol (Group A+P) groups. Aliskiren was given by oral-gavage at a dose of 50 mg/kg/day once daily for 12 weeks. Paricalcitol was given by intraperitoneally at a dose of 0,4 µg/kg/three day of week for 12 weeks. Renal function parameters, oxidative stress biomarkers, mRNA expression of renin-angiotensin system parameters and kidney histology were determined. Results: Group A+P had lower mean albümin-to-creatinine ratio (ACR) (p=0.004) as well as higher creatinine clearance (CCr) (pConclusion: Our data seem to suggest a potential role of aliskiren plus paricalcitol acting synergystically for reducing the progression of diabetic nephropathy in an experimental rat model. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|